Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Accumulated Expenses (2020 - 2025)

Tango Therapeutics has reported Other Accumulated Expenses over the past 6 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $1.3 million for Q4 2025, down 25.71% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (down 25.71% YoY), and the annual figure for FY2025 was $1.3 million, down 25.71%.
  • Other Accumulated Expenses for Q4 2025 was $1.3 million at Tango Therapeutics, down from $1.7 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for TNGX hit a ceiling of $2.7 million in Q3 2024 and a floor of $666000.0 in Q4 2021.
  • Median Other Accumulated Expenses over the past 5 years was $1.5 million (2023), compared with a mean of $1.5 million.
  • Biggest five-year swings in Other Accumulated Expenses: surged 90.83% in 2024 and later plummeted 37.04% in 2025.
  • Tango Therapeutics' Other Accumulated Expenses stood at $666000.0 in 2021, then skyrocketed by 90.24% to $1.3 million in 2022, then rose by 1.58% to $1.3 million in 2023, then skyrocketed by 34.81% to $1.7 million in 2024, then decreased by 25.71% to $1.3 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $1.3 million (Q4 2025), $1.7 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.